1. Articles in category: Immune Therapy

    1-24 of 416 1 2 3 4 ... 16 17 18 »
    1. EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.i High-risk neuroblastoma is an aggressive form of neuroblastoma – the most common solid tumour of childhood that originates outside of the brain.ii Dinutuximab beta is the first targe

      Read Full Article
    2. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      Front Immunol. 2018;9:1355

      Authors: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL

      Read Full Article
      Mentions: Antibody COG
    3. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

      Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

      A major obstacle to the success rate of chimeric antigen receptor (CAR-) T-cell therapy against solid tumors is the microenvironment antagonistic to T cells that solid tumors create. Conventional checkpoint blockade can silence lymphocyte antisurvival pathways activated by tumors, but because they are systemic, these treatments disrupt immune homeostasis and induce autoimmune side effects. Thus, new technologies are required to remodel the tumor milieu without causing systemic toxicities.

      Read Full Article
    4. Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.

      Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.

      Toxins (Basel). 2018 Jun 27;10(7):

      Authors: Rust A, Shah S, Hautbergue GM, Davletov B

      Abstract Immunotoxins are being investigated as anti-cancer therapies and consist of a cytotoxic enzyme fused to a cancer targeting antibody.

      Read Full Article
      Mentions: Antibody MYCN
    5. Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Paediatr Drugs. 2018 Jun 12;:

      Authors: Wedekind MF, Denton NL, Chen CY, Cripe TP

      Abstract Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients.

      Read Full Article
      Mentions: Immunotherapy
    6. Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55

      Authors: Armideo E, Callahan C, Madonia L

      Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.

      Read Full Article
    7. CureWorks Collaborative Launches to Accelerate Development of Immunotherapy Treatments for Childhood Cancers, Increase Access to Clinical Trials

      Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies.

      Read Full Article
      Mentions: Immunotherapy
    8. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

      Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

      Oncoimmunology. 2018;7(6):e1433518

      Authors: Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I

      Read Full Article
    9. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.

      Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.

      Cancers (Basel). 2018 May 31;10(6):

      Authors: Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H

      Abstract With the progress of immunotherapy in cancer, oncolytic viruses (OVs) have attracted more and more attention during the past decade.

      Read Full Article
    10. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clin Cancer Res. 2018 May 21;:

      Authors: Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Nagaraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole DR, Hewitt SM, Sondel PM, Seeger RC, Maris JM, Khan J

      Read Full Article
      Mentions: MYCN
    11. Emerging role of immunotherapy for childhood cancers.

      Emerging role of immunotherapy for childhood cancers.

      Chin Clin Oncol. 2018 Apr;7(2):14

      Authors: Handgretinger R, Schlegel P

      Abstract Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients.

      Read Full Article
      Mentions: Immunotherapy
    12. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    13. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.

      Biomed Res Int. 2018;2018:1812535

      Authors: Vanichapol T, Chutipongtanate S, Anurathapan U, Hongeng S

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in childhood with 5-year survival rate of 40% in high-risk patients despite intensive therapies.

      Read Full Article
      Mentions: Immunotherapy
    14. Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

      Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.

      J Pediatr Hematol Oncol. 2018 Apr 20;:

      Authors: Fassel H, Bussel JB, Roberts SS, Modak S

      Abstract Thrombocytopenia, a serious complication of myelosuppressive chemotherapy in cancer patients, is managed with platelet transfusions until recovery of platelet counts. However, children receiving chemotherapy can rarely develop immune thrombocytopenia (ITP) that is refractory to transfused platelets.

      Read Full Article
    15. Treatment and outcome of adult-onset neuroblastoma.

      Treatment and outcome of adult-onset neuroblastoma.

      Int J Cancer. 2018 Mar 25;:

      Authors: Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S

      Abstract Adult-onset of neuroblastoma is rare and little is known about its biology and clinical course. There is no established therapy for adult neuroblastoma.

      Read Full Article
    16. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

      Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

      Transfusion. 2018 Mar 13;:

      Authors: Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA

      Read Full Article
    17. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.

      Pharm Res. 2018 Mar 07;35(4):85

      Authors: Gholizadeh S, Dolman EM, Wieriks R, Sparidans RW, Hennink WE, Kok RJ

      Abstract PURPOSE: Sepantronium bromide (YM155) is a hydrophilic quaternary compound that cannot be administered orally due to its low oral bioavailability; it is furthermore rapidly eliminated via the kidneys.

      Read Full Article
    18. TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy.

      TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy.

      Int J Mol Sci. 2018 Mar 02;19(3):

      Authors: Batzke K, Büchel G, Hansen W, Schramm A

      Abstract Galectin-1 (Gal-1) has been described to promote tumour growth by inducing angiogenesis and to contribute to the tumour immune escape.

      Read Full Article
    19. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PLoS Med. 2018 Jan;15(1):e1002497

      Authors: Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD

      Read Full Article
      Mentions: PD-1
    20. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN

      Read Full Article
      Mentions: Antibody Treatment
    21. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma

      The monoclonal anti-GD2 antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients. Here, we investigated the inflammatory response and treatment tolerance of long-term infusion (LTI) of ch14.18/CHO (10 × 10 mg/m2; 24 hr) in combination with subcutaneous (s.c.) IL-2 in a single center program.

      Read Full Article
      Mentions: Antibody Treatment
    1-24 of 416 1 2 3 4 ... 16 17 18 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) SIOPEN
    2. (1 articles) COG
  4. Researches in the News

    1. (3 articles) Immunotherapy
    2. (2 articles) Antibody
    3. (1 articles) Nanoparticles
    4. (1 articles) MYCN
  5. Treatments in the News

    1. (1 articles) Surgery
    2. (1 articles) Side Effects